OICR-9429

Cat. No.:	HY-16993		
CAS No.:	1801787-56	-3	
Molecular Formula:	C ₂₉ H ₃₂ F ₃ N ₅	03	
Molecular Weight:	555.59		
Target:	Histone Me	thyltrans	ferase; Apoptosis
Pathway:	Epigenetics	; Apoptos	sis
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year


SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	1.7999 mL	8.9994 mL	17.9989 mL
	Slock Solutions	5 mM	0.3600 mL	1.7999 mL	3.5998 mL
		10 mM	0.1800 mL	0.8999 mL	1.7999 mL
Vivo		lubility information to select the app one by one: 10% DMSO >> 40% PEC) >> 45% saline	i
		g/mL (4.50 mM); Clear solution			
		one by one: 10% DMSO >> 90% (20 g/mL (4.50 mM); Clear solution	% SBE-β-CD in saline)		
		one by one: 10% DMSO >> 90% cor g/mL (4.50 mM); Clear solution	n oil		

BIOLOGICAL ACTIVITY

Description	OICR-9429 is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) ^[1] .
IC ₅₀ & Target	IC50: 67.74 μM (T24 cell); 0.41 μM (UM-UC-3 cell); 121.42 μM (TCCSUP) $^{[1]}$





Product Data Sheet

In Vitro

OICR-9429 (0-10 μ M, 48 h) shows high sensitivity for T24, UM-UC-3 with IC₅₀ values of 67.74 μ M and 70.41 μ M, respectively^[1]. OICR-9429 (0-10 μ M, 48 h) shows low sensitivity for TCCSUP with IC₅₀ values of 121.42 μ M^[1].

OICR-9429 (70 μ M, 120 μ M, 140 μ M and 240 μ M; 48 h) reduces BCa cell viability by decreasing WDR5-mediated H3K4me3^[1]. OICR-9429 (70 μ M, 120 μ M, 140 μ M and 240 μ M; 48 h) inhibits the proliferation of BCa cells by regulating the G1/S phase transition^[1].

OICR-9429 (70 μ M, 120 μ M, 140 μ M and 240 μ M; 24 h) enhances apoptosis of BCa cells in a time-dependent and dose-dependent manner and promotes cisplatin chemosensitivity in BCa cells^[1].

OICR-9429 (70 μ M, 120 μ M, 140 μ M and 240 μ M; 24 h, 48 h) suppresses the metastatic behaviour of bladder cancer cells^[1]. OICR-9429 (70 μ M, 120 μ M, 140 μ M and 240 μ M; 48 h) suppresses PD-L1 expression induced by IFN- γ in BCa cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	BCa cell lines (T24, UM-UC-3 and TCCSUP)
Concentration:	70 μM, 120 μM, 140 μM and 240 μM
Incubation Time:	5 days
Result:	Had a low proliferation rate and remarkably reduced the number of colonies formed by the three BCa cell lines in a dose-dependent manner.

Cell Cytotoxicity Assay^[1]

Cell Line:	BCa cell lines (T24, UM-UC-3 and TCCSUP)
Concentration:	0-10 μΜ
Incubation Time:	48 h
Result:	Inhibited cell viability in a dose-dependent manner in BCa cell lines.

Apoptosis Analysis^[1]

Cell Line:	BCa cell lines (T24, UM-UC-3 and TCCSUP)
Concentration:	70 μM, 120 μM, 140 μM and 240 μM
Incubation Time:	24 h
Result:	Showed no obvious apoptotic cells for 24 h but the apoptotic rate was significantly increased at 72 h and upregulated caspase 3/7 activity.

Cell Migration Assay ^[1]

Cell Line:	BCa cell lines (T24, UM-UC-3 and TCCSUP)
Concentration:	70 μΜ, 120 μΜ, 140 μM and 240 μM
Incubation Time:	24 h, 48 h
Result:	Reduced the migratory speed and decreased the migration of the three BCa cell lines.

Cell Invasion Assay^[1]

Cell Line:	BCa cell lines (T24, UM-UC-3 and TCCSUP)
Concentration:	70 μM, 120 μM, 140 μM and 240 μM
Incubation Time:	24 h, 48 h

Result:	Decreased the invasion of the three BCa cell lines.
Western Blot Analysis ^[1]	
Cell Line:	BCa cell lines (T24, UM-UC-3 and TCCSUP)
Concentration:	70 $\mu M,$ 120 $\mu M,$ 140 μM and 240 μM
Incubation Time:	48 h
Result:	Showed significant downregulation of H3K4me3 in treated cells but not WDR5 or total H Reduced the expression of PD-L1 induced by IFN-γ in a dose-dependent manner at both the RNA and protein levels.
RT-PCR ^[1]	
Cell Line:	BCa cell lines (T24, UM-UC-3 and TCCSUP)
Concentration:	70 μM, 120 μM, 140 μM and 240 μM
Incubation Time:	48 h
Result:	Downregulated some genes related to the cell cycle, such as CDK1, PLK1, CCNE2, CCNB CCNA2, AURKA, and E2F1, genes related to apoptosis and DNA repair, such as BIRC5, XRCC2, AURKA, E2F1, and MCM2, and genes related to metastasis, such as AURKA and FOXM1.
Cell Cycle Analysis ^[1]	
Cell Line:	BCa cell lines (T24, UM-UC-3 and TCCSUP)
Concentration:	70 μM, 120 μM, 140 μM and 240 μM
Incubation Time:	48 h
Result:	Increased the cell population in the G0/G1 phase of three BCa cells and reduced cell population in the S and G2/M phases.
cisplatin for BCa cells in	60 mg/kg, i.p) targeting WDR5 not only suppressed tumour proliferation and enhance the effica vivo but also reduced the toxicity and side effects for normal tissues ^[1] . ntly confirmed the accuracy of these methods. They are for reference only.
Animal Model:	xenograft mouse model $^{[1]}$
Dosage:	30 mg/kg, 60 mg/kg
Administration:	30 mg/kg, 60 mg/kg, i.p.
Result:	Suppressed tumour growth, small tumours and enhanced tumour sensitivity.

CUSTOMER VALIDATION

• Nat Commun. 2019 Aug 21;10(1):3761.

In Vivo

- J Exp Clin Cancer Res. 2022 May 7;41(1):168.
- Clin Transl Med. 2024 Jan;14(1):e1539.
- Cell Rep. 2023 Apr 21;42(5):112423.
- Acta Pharmacol Sin. 2021 Apr 13.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Jingtong Zhang, et al. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer. J Exp Clin Cancer Res. 2021 Jun 21;40(1):203.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA